Call for Abstract

18th World Hematology Congress, will be organized around the theme “Breezes of transformation and revolution in Hematology”

Hematology Congress 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Hematology Congress 2020

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Cardiovascular problems vis-à-vis blood and the immune system that provides laboratory values regarding blood, the cardiovascular system and secures cardiovascular diseases from the Chinese medicine and western medicine perspectives.

Cardio-Oncology is to find a balance between oncologic efficacy and reducing antagonistic cardiovascular effects over timely publication and broadcasting of research. Cardiac imaging and transthoracic echocardiography play a crucial role in the baseline assessment and serial follow-up of cardio-oncology patients. Scientific indication in the administration of cardiovascular hitches of onco-hematological patients is unusual, as these patients have been systematically omitted from clinical trials and up-to-date approvals are based on expert consent. Cardio-onco-hematology which allow its claim in regular clinical preparation so to promote the expansion of local multidisciplinary crews, to rally the cardiovascular health of patients with cancer.

  • Track 1-1Amyloid cardiomyopathy
  • Track 1-2Echocardiographic
  • Track 1-3Cardiotoxicity
  • Track 1-4Chemotherapy
  • Track 1-5Cancer Genomics

Haemorrhage disorders are instigated by vascular malformation or impairment. They are linked with cutaneous or mucosal flat or palpable purpura. These disorders are a heterogeneous assembly of circumstances categorized by easy staining, petechiae, mucosal bleeding, ecchymosis and impulsive bleeding from small vessels. The fundamental imperfection is stated to be moreover in the vessels themselves or in the perivascular connective tissue.

Worth mentioning, the commonly used “purpura” is generally describe subcutaneous bleeding, that may be linked to blood vessel wall abnormalities (described here) or platelet abnormalities. Of which some are hereditary and while the others are acquired. 

  • Track 2-1Thrombocytopenias
  • Track 2-2Henoch-Schönlein purpura
  • Track 2-3Osler-Weber-Rendu disease
  • Track 2-4Haemolytic-uraemic syndrome
  • Track 2-5Drug reactions
  • Track 2-6Steroid purpura
  • Track 2-7Senile purpura
  • Track 2-8Hlers-Danlos syndrome
  • Track 2-9Marfan syndrome
  • Track 2-10Osteogenesis imperfecta

The crossing point amongst hematology and neurology is comprehensive, and neurological complications in the course of hematologic ailment are recurrent and diverse. Polycythemia, in which there are increased numbers of red blood cells with iron deficient. Polycythemia and the comparative Sideropenia lead to amplified blood viscosity with connected neurological symptoms and signs.

Haematological conditions that lead into neurological manifestations are Thrombophilia, antiphospholipid antibody syndrome, thrombotic thrombocytopenic purpura, sickle cell, myeloma, leukemias, lymphomas and clonal disorders. These are considered into benign and malignant situations

  • Track 3-1Seizures and epilepsy
  • Track 3-2Headaches
  • Track 3-3Developmental disorders
  • Track 3-4Brain tumors
  • Track 3-5Sleep disorders
  • Track 3-6Nerve and muscle diseases
  • Track 3-7Movement disorders
  • Track 3-8Metabolic diseases

Blood Transfusion is a medical practice where donated blood is transfused to a recipient. It is a lifesaving, benign procedure. These are used to treat several medical conditions such as iron deficiency Anemia, Sickle cell ailment, severe haemorrhage generally from surgery, childbirth or a serious fate. What's more whole blood or blood components (red blood cells, white blood cells, plasma and clotting factors) are castoff depending on the state of the patient.

For the reason that high-end medical involvements, the demand for blood and blood components is increasing steadily all over the world. The mandate for blood is progressively growing even though some branches of medicine have brought down its inevitability.  There will be reform of blood transfusion facilities for healthier effectiveness and service delivery. The number of blood banks will drop, and high-volume, technically up-clambered central blood banks will function in their place to diminish the costs of procedure. All together, we predict good scenarios for transfusion medicine specialists by the year 2025, at best in the developing countries. Transfusion medicine has good prospective R&D approaches in Stem Cell Research.

Adverse effects:

Immunologic reaction



  • Track 4-1Immunologic Reaction
  • Track 4-2Immunologic Reaction
  • Track 4-3Infection
  • Track 4-4Inefficacy
  • Track 4-5Sickle Cell Disease
  • Track 4-6Hemostasis
  • Track 4-7Thrombosis
  • Track 4-8Cellular Therapies

Hematology medical attendants are the experts in taking care of the patients with blood related infections. They know about patients' history, and they will help the hematologist to analyse and treat the blood related illnesses. The most imperative thing is to teach the patients to deal with the illnesses gallantly.

They can recommend the prescription as they know about the state of the condition. They perhaps spread their assistance in the transplantation of the blood as well. Keeping in mind the end goal to seek after the learning of hematology nursing, one must finish the recognition in nursing or four year college education in nursing and the gigantic feeling of certainty happens when they have the involvement in the particular field. Hematology nursing is frequently identified with the hematology oncology.

  • Track 5-1Hematology nursing products
  • Track 5-2Paediatric hematology products
  • Track 5-3Clinical hematology nursing
  • Track 5-4Blood cancer pain management
  • Track 5-5Surgical hematology nursing
  • Track 5-6Medical Oncology Nursing

case report is usually considered a kind of anecdotal proof. Given their intrinsic method limitations, including absence of statistical sampling, case reports are placed at the foot of the hierarchy of clinical proof, beside case series. However, Hematology case reports do have genuinely helpful roles in medical research and evidence-based drugs. Specifically, they need facilitated recognition of recent diseases and adverse effects of treatments. For instance, recognition of the link between administration of teratogen to mothers and malformations in their babies was suggested by the report of a specific case. Case reports have a task in pharmacovigilance. They will additionally facilitate understand the clinical spectrum of rare diseases, moreover as uncommon presentations of common diseases. They can facilitate generate study hypotheses, as well as plausible mechanisms of disease. Case reports might also have a task to play in guiding the personalization of treatments in clinical follow. Therefore it's important to incorporate case reports in Hematologists conferences.

  • Track 6-1General Hematology
  • Track 6-2Pathology
  • Track 6-3Oncology
  • Track 6-4Lymphomas
  • Track 6-5Leukemias
  • Track 6-6Pediatric Hematology-Oncology
  • Track 6-7Pediatric Hemato-Cardiology

Hematologic cancer is the mostly spread and most common disorder among other Blood disorders and is a very important aspect of Blood disorder research. Blood malignancies affect the performance and formation of your blood cells. Cancerous cells restrict your blood from performing its important/regular functions, like prohibiting from serious bleeding or fighting with foreign body/infections agents. A chief part of blood-based investigation is going on in this field. Leukaemia mainly affects the white blood cells (WBCs) and are closely linked to the lymphomas and some of them are deeply related to the adult T cells leukaemia, these disorders comes under the lymph proliferative disorders. The cancer which originates from WBCs (white blood cells) is known as lymphoma and this type of disorder is mainly seen in Hodgkin lymphoma these diseases can be treated with hematopoietic stem cell transplantation, radiation therapy and chemotherapy. The bone marrow in which a large number of white blood cells develop that leads to multiple myeloma

  • Track 7-1Hodgkin and non-Hodgkin lymphoma
  • Track 7-2Myelogenous leukemia
  • Track 7-3Acute lymphocytic
  • Track 7-4Chronic lymphocytic
  • Track 7-5Multiple Myeloma

For the principle detection of blood disorders, a Physician generally go for Complete blood count (CBC). This is the basic test after that to diagnose a person's blood disorder, the doctor usually must do further blood tests Once a doctor/consultant finds that something is wrong with the blood cell types, many additional tests are available for further detection of disease. Doctors can measure proportion of the different types of WBCs (white blood cells) and can also determine subtypes of these cells by assessing certain markers on the surface of the cells. Assessments are made to measure the capacity of white blood cells to fight foreign body/ infection, to evaluate the functioning of blood platelets and their ability to clot and to check the contents of red blood cells to help determine the cause of anaemia or why the cells are not functioning properly. Most of these tests are done on blood samples, but sometime require a bone marrow sample as well for Bone Marrow Examination. Based on the diagnosis, Hematologists go for the apt treatment for specific problem.  Present days we have numerous approaches to treat blood malignancies such as Chemotherapy, Radiation therapy etc. Today’s advanced procedures such as gene therapy is being used to treat Blood ailments. Investigators are endeavouring to search out ways that to correct the defective genes that cause Blood Disorders. Nevertheless, Gene therapy hasn't established to the resolve that it's accepted therapy for Blood Disorder. Though, investigators still take a look at gene therapy in clinical trials. Bone Marrow Transplantation, Hematopoietic stem cell therapy and Cord blood transplantation are new rising varieties of treatment for blood disorders

  • Track 8-1Bone Marrow Transplantation
  • Track 8-2Hematopoietic stem cell therapy
  • Track 8-3Cord blood transplantation
  • Track 8-4Gene therapy
  • Track 8-5Chemotherapy
  • Track 8-6Radiation therapy

Cancer Genomics & Metabolomics. Cancer genomics is a sub-field of genomics that personifies cancer-linked or cancer associated genes. Whereas Metabolomics is the quantification of small molecules formed by metabolic progressions within a biological model. Metabolomics datasets contain a wealth of information that reflect the disease state and are consequent to both genetic variation and environment.

Because cancer is a genomic disease, genomic profiling is an undeniably important tool for precision oncology. Precision Oncology alludes to the fitting of therapeutic cancer treatment to the individual qualities of every patient.

  • Track 9-1Cancer Metabolomics
  • Track 9-2Precision Oncology
  • Track 9-3Biomarker Metabolomics
  • Track 9-4Cancer immunotherapy
  • Track 9-5Targeted therapeutics
  • Track 9-6Active immunotherapies

Developments in electronic imaging, computers, and the Internet have given rise to in the speedy emergence of digital imaging in pathology.

The Bloodhound system is an instrument that is designed to print blood onto a microscope slide with a controlled method, automatically stain cells, perform a CBC with WBC differential, and locate WBCs by digital imaging, all in an analyser with a footprint of 42 inches.

Negligible Hematology Analyzer Plus Blood Smear Digital Imaging/ Analysis make available better Clinical Hematology consequences than a Compound Hematology Analyzer.

Digital Imaging works in daily routine for leukocytes in peripheral blood and other fluids, is reliable, accurate and displays a high blast cell sensitity.

  • Track 10-1Lymphocyte Pathology
  • Track 10-2Blast cells
  • Track 10-3Red Blood Cell Morphology
  • Track 10-4Quality Survey Issues in Digital Imaging
  • Track 10-5Integration in daily practice
  • Track 10-6Digital Imaging of RBC’s

The second foremost basis of death in the world next to cardiovascular diseases is Cancer. Different types of cancers affect diverse organs of the body, roughly of them are Brain cancer, Head and Neck Cancer, Oral cancer, Lung cancer, Breast cancer, Liver cancer, Prostate cancer, Gastric cancer, Pancreatic cancer, Kidney (Renal Cell) cancer, Leukemia and numerous. Most common spots that are influenced by cancer in men are Lung, prostate, colon, rectum, stomach and liver, whereas in women are breast, colon, rectum, lung, cervix and stomach.

Aiming cancer metabolism has the possibility to lead to major advances in cancer healing. Recent developments in diagnosis and therapy of cancers have directed to an increase in cancer survival and hence, there is a greater emphasis on quality beside quantity of survival. Added exploration on the quality-oriented cancer remedies primes to quality-oriented lives in forthcoming.

As per the calculations of researchers till now more than 200 types of the cancers have been identified. The menace do subject to, upon the area/Organ involved by Cancer.

  • Track 11-1Gastric Cancer
  • Track 11-2Blood cancers
  • Track 11-3Skin cancer
  • Track 11-4Breast Cancer
  • Track 11-5Colorectal Cancer
  • Track 11-6Bone cancer
  • Track 11-7Paediatric cancers
  • Track 11-8Gynaecologic Cancers

Hematopoietic cancers are dealt with tumours of immune system cells. Most of them are encompassed of cells that are functionally heterogeneous with only a subdivision being in charge for tumor care. Leukemias are “liquid tumors” in the blood and are derived from the transformation of either a hematopoietic precursor in the bone marrow or a mature hematopoietic cell in the blood. Leukemias can be lymphoid or myeloid, and acute or chronic.

Most hematopoietic malignancies are comprised of cells that are functionally heterogeneous with only a subset being responsible for tumor maintenance.

The thorough perceptive of accumulation of genetic/epigenetic event progressions could prime to development of therapeutics that more effectively treat hematopoietic malignancies and potentially other cancers.

Hematopoietic cancers (HCs) are malignancies of immune system cells, associated with gross chromosomal abnormalities such as translocations.

Improvements in diagnosis and therapy, including hematopoietic stem cell transplantation and molecularly targeted strategies, have increased patient survival.

  • Track 12-1 Hematopoietic Cancer
  • Track 12-2Leukemias
  • Track 12-3Myeloma
  • Track 12-4Lymphoma
  • Track 12-5Recurring Translocation
  • Track 12-6Hodgkin Lymphoma
  • Track 12-7Non-Hodgkin lymphoma
  • Track 12-8Immunotherapy

Stem cell therapy is the treatment where stem cells are used to prevent a disease or condition. Haematopoietic stem cells are usually derived from bone marrow, or peripheral blood. Bone marrow transplantation is widely used stem cell therapy. It may be autologous, allogeneic or syngeneic.

Stem cell research deals with research and publication of high-quality manuscripts related to stem cells. Stem cells are cells of multicellular organisms that can differentiate into other types of cells. They can divide more cells of the same type of stem cells. For a cell to be considered a stem cell, it should be self-renewing and must be either totipotent or pluripotent. Various types of stem cells such as embryonic stem cells, foetal and adult stem cells tissue specific stem cells, haemopoietic stem cells, cancer stem cells are known. Haemopoietic stem cells that give rise to other blood cells by a process called Hemopoiesis in the red bone marrow. Haemopoietic stem cell transplants are used in the treatment of cancers and other immune system disorders. 

  • Track 13-1Brain and spinal cord injury
  • Track 13-2Neurodegeneration
  • Track 13-3Blood cell formation
  • Track 13-4Pancreatic beta cells
  • Track 13-5Orthopaedics
  • Track 13-6Wound healing
  • Track 13-7Infertility

One of three foundations of blood-forming cells used in transplants is Cord Blood whereas the other two bases are bone marrow and peripheral blood stem cells.

The inoculation of umbilical cord blood to re-establish an individual's own blood production system blocked by anticancer drugs, radiation therapy, or both. Human cryopreserved CD34+ cells from cord blood, bone marrow, and mobilized blood. CD34+ cells differentiate into all other white blood cells. More Cells. Relevant Results. Types: Cells, Media, Assays. Cancers can be treated through Stem cell transplants, including peripheral blood, bone marrow, and cord blood transplants. The first successful cord blood transplant (CBT) was done in 1988 in a child with Fanconi Anemia. The theory of the learning is twofold unit umbilical cord blood transplantation in adults will be connected with a one-year endurance rate of at least 40%.


  • Track 14-1Human Leukocyte Antigen (HLA) Matching
  • Track 14-2Graft-Versus-Host Disease
  • Track 14-3Diversity
  • Track 14-4Infectious Disease Transmission
  • Track 14-5Clinical Data
  • Track 14-6Engraftment
  • Track 14-7Storage
  • Track 14-8Research and Clinical Trials

It is the branch of medical treatment that deals with identification and therapy of blood ailments and blood malignances. This includes supervision of chemotherapy and transfusion.

Clinical Hematology doctors are dealt in the following areas haemato-oncology, haematology and bone marrow transplantation, principal the clinical facilities (Adult & Paediatric) along with a Haemato-Pathologist, auxiliary in hematopathology amenities.

Ailments cured under clinical Haematology: Acute Leukemia, Chronic Leukemia, Plasma Cell disorders, Lymphoma – Hodgkin / Non-Hodgkin, Myeloproliferative Neoplasms, Thalassemia and other haemoglobinopathies, all types of coagulation and thrombotic disorders and Haemoglobin and platelet disorders.


  • Track 15-1Anaemia
  • Track 15-2Leucopenia
  • Track 15-3Thrombocytopenia
  • Track 15-4Polycythemia
  • Track 15-5Polycythemia
  • Track 15-6Leucocytosis
  • Track 15-7Thrombocytosis
  • Track 15-8Hereditary myeloid malignancies
  • Track 15-9Clonal Hematopoiesis
  • Track 15-10NK/T-cell lymphomas

Paediatric haematology is a branch of haematology dealing with the general haematological problems seen in neonates or paediatric patients. Other issues such as blood counts, Polycythaemia, Neonatal anaemia, Anaemia of prematurity, Haemolytic anaemia in the neonate, Congenital red cell defects, acquired red cell defects, Hyperbilirubinemia, Congenital dyserythropoietic anaemia, Acquired red cell aplasia, Neutropenia, leukaemia etc are dealt under Paediatric Haematology. Haematopoiesis is different in paediatric patients and neonates compared to adults. By birth, virtually all bone marrow cavities are actively hematopoietic. In infantile, haematopoiesis transfers to central bones (vertebrae, sternum, ribs, pelvis). The red cells of the new-born are macrocytic and the blood film from a new-born infant shows macrocytic normochromic cells, polychromasia, and a few nucleated red blood cells.

Unfluctuating in healthy infants may be a mild anisocytosis and poikilocytosis. Blood viscosity, oxygen delivery, Iron and transferring content, red cell antigens and many other features are different in neonates and children compared to the adults. Hence a thorough research enabling a proper diagnosis and treatment of all the haematological disorders in neonates and paediatric patients is highly necessary.

  • Track 16-1Acanthocytosis
  • Track 16-2Cancer infection control
  • Track 16-3Thrombocytopenia in new-born
  • Track 16-4Systemic disorders
  • Track 16-5Anisocytosis
  • Track 16-6Congenital dyserythropoietic anaemia

The worldwide market of the hematological medications in top point as it is frequently anticipated to be enhanced over the couple of decades. As per the worldwide market expert the haematology medicate and demonstrative market is relied upon to develop at the rate of 7.5% from 2015-2020.

Some of the top pharmacy industries producing Biological Drugs and Generic Drugs incorporate. Takeda oncology, Bristol-Mayers Squibb, Bristol-Myers Squibb, Boehringer Ingelheim, Roche, Novartis, Celgene, Johnson and Johnson, Lilly, Takeda, AstraZeneca, Merck and Co., Amgen, Janssen biotech, Pfizer, Astellas, Bayer, Otsuka, Sanofi, Eisai, AbbVie, Merck KGaA, Pharmacyclics and Incyte.

  • Track 17-1Biological drugs
  • Track 17-2Generic drugs
  • Track 17-3Increased investments
  • Track 17-4Healthcare expenditures

The channel of medicine that perturbed with the learning of the origin, diagnosis, therapy, and anticipation of diseases related to blood. It comprises treating diseases that mark the production of blood and its components, for example blood cells, blood proteins, bone marrow, haemoglobin, platelets, spleen, blood vessels and the method of coagulation. Such ailments might embrace hemophilia, blood clots, added bleeding disorders and blood cancers such as leukaemia, lymphoma and multiple myeloma. The test centre slog that goes into the study of blood is recurrently performed by a medical technologist or medical laboratory scientist.

Treating of blood disorder may vary for every particular disorder, this can include use of coagulation factor support, immune modulating therapies, chemotherapy, bone marrow transplantation palliative care must be taken for the patients with complex disorder. Usually, through physical investigations, medical reports are used to spot the ailments by physicians to initiate the best therapy.


  • Track 18-1Hemochromatosis
  • Track 18-2Idiopathic thrombocytopenic purpura
  • Track 18-3Malaise
  • Track 18-4Bone marrow transplantation
  • Track 18-5Blood transfusion

Biomarkers are the biological molecules found in blood, other body fluids, or tissues, which explains a symbol of a normal or anomalous progression, or of a condition or illness. These are used to see how well the body answers to a therapy for an illness or disorder. These are also termed as molecular marker and signature molecule.

cancer biomarker is a gene or substance that reveal the presence of cancer in the body that are particularly associated with genetic mutations, which determine whether individuals are susceptible to particular type of cancer.

Biomarkers are used in three principal modes in medicine and cancer research:

1. To aid detect complaints in the identification of early phase Malignance’s

2. To predict how antagonistic an ailment is (Prognostic)

3. To envisage how sound a patient will retort to therapy


  • Track 19-1Genetic markers
  • Track 19-2Tumour markers
  • Track 19-3Cancer biomarkers
  • Track 19-4Diagnostic Biomarker
  • Track 19-5Biomarker Discovery

Immunohematology referred to be blood banking. This is the laboratory medicine dealing up with preparing blood components, blood for appropriate selection and transfusion and also components that are compatible for transfusion which is helpful in case of severe blood loss or low blood levels. If the selection and compatibility fail this may directs to harm the kidneys, lungs and might be life threating. Transfusion can be recommended in case of illness, burns, cancer, and injury. Individuals get immunized when there are previous transfusions of blood or in case of pregnancy. Red blood cells contain antigens and protein markers on their surfaces, if recipient or donors red blood cells don’t contain this antigen the antigen lacking individual will lead to form antibodies which destroys the red blood what blood banks screens, typing and cross matching are carried out for blood and its components before the transfusions.

If immune system of recipient attacks the donor red blood cells this state knows to be haemolytic reaction. Sometimes hives and itching can also be observed.


  • Track 20-1Transfusion related acute lung injury (TRALI)
  • Track 20-2Acute kidney failure
  • Track 20-3Antibody screening
  • Track 20-4Gel Testing
  • Track 20-5Pretransfusion testing module
  • Track 20-6Rh-sensitization